Q2 revenue down 10.5%, profit down 15.9%; cash outflow persists

Revenue DeclineNegative Operating CashflowResults View source PDF Explain this filing

JTLIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹59.06

prior close

₹59.82

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-0.4% vs market

Iron & Steel Products peers, median of 92sector-0.6%-0.2% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.2 pts less than its Iron & Steel Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.8

15m

-0.9

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.4-0.4-0.6-0.2

Next day

+1.0-0.6+1.6-0.6+1.6

+1.4+0.3+1.1-0.6+2.0

+2.7+0.2+2.5-1.3+4.0

+2.1+0.1+2.0-1.2+3.3

+9.2+0.7+8.5-1.4+10.7

+15.8-0.3+16.1-3.4+19.2

15d

+12.2-2.0+14.2-4.2+16.4

+1.9-5.7+7.6-7.2+9.2

+4.8-7.8+12.6-8.4+13.2

+10.5-4.6+15.1-9.7+20.2

UpDownMarket · Nifty Microcap 250Sector · Iron & Steel Products peers, median of 92Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved unaudited Q2 and half-year results. Consolidated Q2 revenue was ₹429.30 crore, down 10.5%, and profit was ₹22.16 crore, down 15.9%. Half-year revenue was ₹973.16 crore, down 2.2%, and profit ₹38.71 crore, down 32.2%. Operating cash outflow was ₹80.32 crore. The limited review found no material misstatement. The company also forfeited ₹168.75 crore linked to 2.5 crore warrants.

Likely market impact

Falling sales and profit plus continued operating cash outflow may pressure sentiment and the stock.